FDA Warns of Bladder Cancer Risk with Actos

After the U.S. Food and Drug Administration (FDA) cautioned in June that the diabetes drug pioglitazone (known as brand name “Actos”) presents an increased risk of bladder cancer for ongoing users, the start of a class action lawsuit involving dozens of affected individuals quickly followed in September.

Specifically, the drug is prescribed to adults with type 2 diabetes mellitus to assist with the regulation of blood sugar. From January 2010 to October 2010, the FDA reported about 2.3 million individuals with prescriptions that contained the substance. In addition to Actos, pioglitazone is also found in Actoplus Met, Actoplus Met XR, and Duetact.

The FDA issued the following guidelines regarding Actos, and any other medical products containing the drug:

  • Do not prescribe it to patients with bladder cancer.
  • Use the drug with discretion with an individual with a medical history of bladder cancer.

Other than the stated primary risk, the agency also gave consumers and patients the following instructions:

  • Do not use the drug if you are receiving treatment for bladder cancer.
  • Immediately notify your health care professional if you experience any of these symptoms: red appearance of the presence of blood in your urine, an urgency to urinate or pain while doing so, or pain in your back or lower abdomen.

Those using any products with pioglitazone, or the primary drug Actos, are instructed by the FDA to speak with their health care provider at once. If you believe you’ve been injured by exposure to pioglitazone, contact the Pennsylvania Actos attorneys with Anapol Weiss at 1(866)735-2792 for a free consultation.

Contact Information